Follow-up Testing for ANA Positive with Nuclear Speckled Pattern

Understanding the Nuclear Speckled Pattern

The nuclear speckled pattern is associated with specific autoantibodies and can indicate various systemic autoimmune rheumatic diseases (SARD), including systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, inflammatory myopathies, and mixed connective tissue disease 2
The American College of Rheumatology recommends that the nuclear speckled pattern should be interpreted in the context of clinical symptoms and other laboratory findings, as stated by the European League Against Rheumatism 1, 2

The European League Against Rheumatism recommends testing for specific extractable nuclear antigens (ENA) should include anti-SSA/Ro and anti-SSB/La for Sjögren's syndrome, anti-Sm and anti-RNP for SLE and mixed connective tissue disease, anti-Topoisomerase-1 for systemic sclerosis, and anti-Jo-1 for inflammatory myopathies 1, 2
If clinical suspicion for SLE exists, the American College of Rheumatology advises anti-dsDNA antibody testing, with the Farr assay and Crithidia luciliae immunofluorescence test (CLIFT) offering high clinical specificity for anti-dsDNA detection 1

The American College of Rheumatology states that ANA testing is primarily intended for diagnostic purposes, not for monitoring disease progression, and results of assays for antibodies to specific ENAs should be reported separately, including negative results 1, 2
Different laboratories may use different methods and cutoffs for ANA testing, affecting result interpretation, as noted by the European League Against Rheumatism 2

A positive ANA with nuclear speckled pattern alone is not diagnostic of any specific autoimmune disease and requires clinical correlation, according to the European League Against Rheumatism 2
In cases of high clinical suspicion, physicians should request determination of antibodies to specific ENAs regardless of the ANA result, as some autoantibodies may be present in ANA-negative patients, as recommended by the American College of Rheumatology 1, 2
False negatives can occur with automated methods, and indirect immunofluorescence assay (IIFA) remains the reference standard, as stated by the American College of Rheumatology 1, 2

Laboratories should specify the methods used for detecting ANA when reporting their results, and ANA patterns should be reported according to standardized terminology, as recommended by the American College of Rheumatology 1
The method used for anti-dsDNA antibody detection should be included in the test result, according to the European League Against Rheumatism 1